ZA965666B - Preparations and methods for the treatment of t cell mediated diseases - Google Patents

Preparations and methods for the treatment of t cell mediated diseases

Info

Publication number: ZA965666B
Authority: ZA; South Africa
Prior art keywords: cell mediated; preparations; treatment; mediated diseases; methods
Prior art date: 1995-07-05

Application number

ZA965666A

Other languages

English (en)

Inventor

Irun R Cohen

Dana Elias

Meir Shinitzky

Original Assignee

Yeda Res & Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-07-05

Filing date

1996-07-04

Publication date

1997-01-27

1996-07-04 Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev

1997-01-27 Publication of ZA965666B publication Critical patent/ZA965666B/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Molecular Biology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Rehabilitation Therapy (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Marine Sciences & Fisheries (AREA)

ZA965666A 1995-07-05 1996-07-04 Preparations and methods for the treatment of t cell mediated diseases ZA965666B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IL11445895A IL114458A0 (en)	1995-07-05	1995-07-05	Therapeutic preparations for treatment of T cell mediated diseases

Publications (1)

Publication Number	Publication Date
ZA965666B true ZA965666B (en)	1997-01-27

Family

ID=11067727

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA965666A ZA965666B (en)	1995-07-05	1996-07-04	Preparations and methods for the treatment of t cell mediated diseases

Country Status (22)

Country	Link
EP (1)	EP0837672B9 (xx)
JP (2)	JP4357595B2 (xx)
KR (1)	KR100435040B1 (xx)
CN (1)	CN1102382C (xx)
AT (1)	ATE254451T1 (xx)
AU (1)	AU714970B2 (xx)
CA (1)	CA2226013C (xx)
CZ (1)	CZ298A3 (xx)
DE (1)	DE69630787T2 (xx)
DK (1)	DK0837672T3 (xx)
ES (1)	ES2211963T3 (xx)
HR (1)	HRP960315A2 (xx)
HU (1)	HU223081B1 (xx)
IL (2)	IL114458A0 (xx)
MX (1)	MX9800190A (xx)
NO (1)	NO320363B1 (xx)
PT (1)	PT837672E (xx)
SI (1)	SI0837672T1 (xx)
UY (1)	UY24275A1 (xx)
WO (1)	WO1997002016A1 (xx)
YU (1)	YU40796A (xx)
ZA (1)	ZA965666B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5993803A (en) *	1996-08-30	1999-11-30	Yeda Research And Development Co., Ltd.	Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
US6022697A (en)	1996-11-29	2000-02-08	The Regents Of The University Of California	Methods for the diagnosis and treatment of insulin-dependent diabetes mellitus
US7541184B2 (en)	2000-02-24	2009-06-02	Invitrogen Corporation	Activation and expansion of cells
US7572631B2 (en)	2000-02-24	2009-08-11	Invitrogen Corporation	Activation and expansion of T cells
IL142536A0 (en) *	2001-04-11	2002-03-10	Yeda Res & Dev	Carriers for therapeutic preparations for treatment of t-cell mediated diseases
EP2301566B1 (en)	2002-05-21	2013-07-03	Irun R. Cohen	DNA vaccines encoding heat shock proteins
US20050084967A1 (en)	2002-06-28	2005-04-21	Xcyte Therapies, Inc.	Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
WO2004098489A2 (en) *	2003-05-12	2004-11-18	Peptor Ltd.	Compositions and methods for modulation of specific epitopes of hsp60
CA2547079A1 (en) *	2003-11-24	2005-06-02	Yeda Research & Development Co. Ltd.	Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases
EP1835933A4 (en)	2005-01-04	2015-01-07	Yeda Res & Dev	HSP60, HSP60-PEPTIDES AND T-CELL VACCINES FOR IMMUNOMODULATION
US9078843B2 (en)	2005-09-22	2015-07-14	Irun R. Cohen	Immunogenic fragments of T-cell receptor constant domains and peptides derived therefrom
JP2019523633A (ja) *	2016-04-29	2019-08-29	アライムファーマシューティカルズ，インコーポレーテッド	組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4395394A (en) *	1979-10-26	1983-07-26	Pfizer Inc.	Use of lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
IL63734A (en) *	1981-09-04	1985-07-31	Yeda Res & Dev	Lipid fraction,its preparation and pharmaceutical compositions containing same
SE8405493D0 (sv) *	1984-11-01	1984-11-01	Bror Morein	Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5114844A (en) *	1989-03-14	1992-05-19	Yeda Research And Development Co., Ltd.	Diagnosis and treatment of insulin dependent diabetes mellitus
IL97709A (en) *	1990-03-30	2005-05-17	Brigham & Womens Hospital	Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis

1995
- 1995-07-05 IL IL11445895A patent/IL114458A0/xx unknown
1996
- 1996-07-02 JP JP50531797A patent/JP4357595B2/ja not_active Expired - Lifetime
- 1996-07-02 DK DK96924371T patent/DK0837672T3/da active
- 1996-07-02 DE DE69630787T patent/DE69630787T2/de not_active Expired - Lifetime
- 1996-07-02 CN CN96196402A patent/CN1102382C/zh not_active Expired - Lifetime
- 1996-07-02 IL IL12275596A patent/IL122755A/en not_active IP Right Cessation
- 1996-07-02 AU AU64844/96A patent/AU714970B2/en not_active Expired
- 1996-07-02 SI SI9630662T patent/SI0837672T1/xx unknown
- 1996-07-02 CA CA2226013A patent/CA2226013C/en not_active Expired - Lifetime
- 1996-07-02 ES ES96924371T patent/ES2211963T3/es not_active Expired - Lifetime
- 1996-07-02 WO PCT/US1996/011373 patent/WO1997002016A1/en not_active Ceased
- 1996-07-02 AT AT96924371T patent/ATE254451T1/de active
- 1996-07-02 EP EP96924371A patent/EP0837672B9/en not_active Expired - Lifetime
- 1996-07-02 PT PT96924371T patent/PT837672E/pt unknown
- 1996-07-02 KR KR10-1998-0700036A patent/KR100435040B1/ko not_active Expired - Fee Related
- 1996-07-02 MX MX9800190A patent/MX9800190A/es unknown
- 1996-07-02 CZ CZ982A patent/CZ298A3/cs unknown
- 1996-07-02 HU HU9802834A patent/HU223081B1/hu active IP Right Grant
- 1996-07-04 ZA ZA965666A patent/ZA965666B/xx unknown
- 1996-07-04 HR HR114458A patent/HRP960315A2/hr not_active Application Discontinuation
- 1996-07-05 YU YU40796A patent/YU40796A/sh unknown
- 1996-07-05 UY UY24275A patent/UY24275A1/es unknown
1998
- 1998-01-02 NO NO19980013A patent/NO320363B1/no not_active IP Right Cessation
2009
- 2009-06-15 JP JP2009141914A patent/JP2009242412A/ja active Pending

Also Published As

Publication number	Publication date
CN1193907A (zh)	1998-09-23
EP0837672A4 (en)	1999-01-27
HUP9802834A3 (en)	2001-08-28
HRP960315A2 (en)	1998-02-28
EP0837672A1 (en)	1998-04-29
PT837672E (pt)	2004-03-31
ATE254451T1 (de)	2003-12-15
CN1102382C (zh)	2003-03-05
MX9800190A (es)	1998-04-30
AU6484496A (en)	1997-02-05
HU223081B1 (hu)	2004-03-29
HUP9802834A2 (hu)	1999-03-29
DE69630787T2 (de)	2004-10-07
JP4357595B2 (ja)	2009-11-04
JP2009242412A (ja)	2009-10-22
UY24275A1 (es)	2000-12-29
CA2226013A1 (en)	1997-01-23
NO980013L (no)	1998-02-19
WO1997002016A1 (en)	1997-01-23
EP0837672B1 (en)	2003-11-19
KR100435040B1 (ko)	2004-08-18
NO980013D0 (no)	1998-01-02
IL114458A0 (en)	1995-11-27
IL122755A0 (en)	1998-08-16
CA2226013C (en)	2012-09-18
CZ298A3 (cs)	1998-06-17
YU40796A (sh)	1998-11-05
SI0837672T1 (en)	2004-04-30
NO320363B1 (no)	2005-11-28
EP0837672B9 (en)	2005-06-15
DE69630787D1 (de)	2003-12-24
ES2211963T3 (es)	2004-07-16
DK0837672T3 (da)	2004-03-22
IL122755A (en)	2004-07-25
JPH11508899A (ja)	1999-08-03
AU714970B2 (en)	2000-01-13
KR19990028738A (ko)	1999-04-15

Publication	Publication Date	Title
ZA965666B (en)	1997-01-27	Preparations and methods for the treatment of t cell mediated diseases
ES2179077T3 (es)	2003-01-16	Acido glutamico decarboxilasa clonada.
ES2530769T3 (es)	2015-03-05	Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno
PT1131065E (pt)	2003-10-31	Fumaratos dialquilicos para o tratamento de doencas autoimunes
EP0751781A4 (en)	1999-09-22	METHOD FOR PREVENTING OR TREATING A DISEASE, CHARACTERIZED BY THE NEOPLASTIC CELLS EXPRESSING CD40
AU3844297A (en)	1998-03-06	Treatment of autoimmune diseases
SI1270595T1 (sl)	2008-12-31	Protitelo proti CCR4 in njegov fragment
ATE206041T1 (de)	2001-10-15	Polyether-blockcopolymer micellare zusammensetzungen zur zielgerichteten verabreichung biologischer stoffe
DK0914144T3 (da)	2001-04-09	Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
ES2164914T3 (es)	2002-03-01	Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
DE69719754D1 (de)	2003-04-17	Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
PT879056E (pt)	2002-10-31	Modulacao da expressao das citocinas th1/th2 atraves de ribavirina em linfocitos t activados
PT952772E (pt)	2005-07-29	Processos de utilizacao de fagocitos mononuclears para promover a regeneracao axonal
IT1319275B1 (it)	2003-09-26	Uso del baclofen nel trattamento dell'astinenza da etanolo.
MXPA03001167A (es)	2004-04-20	Proteinas y peptidos de tension y metodos para su uso.
Chen	2018	What's new about the mechanism of methotrexate action in psoriasis?
Ito et al.	2020	CCR5 is a novel target for the treatment of experimental alopecia areata
HUP9901077A2 (hu)	1999-07-28	Gyógyszerkészítmény T-sejtek által közvetített gyulladásos bőrbetegségek ellen
Ishida et al.	1994	Nutritional and immunological assessment in patients with malignant obstructive jaundice--the influence of preoperative biliary decompression and abdominal surgery
EP1052285A3 (en)	2002-07-24	Method of inducing an antigen-specific anticytotoxic cell
UA28518A (uk)	2000-10-16	Спосіб визначення алергену у хворих на лікарську хворобу
Novales-Li	1996	In vitro immunopharmacologic effect of suramin on modifying Th-subset cytokine levels in splenocytes and T-cell clones: a therapeutic application for autoimmune disease
Dorr	1988	Modulatory effects of cimetidine on the bovine immune system: Cell-mediated immunity, suppressor cell function and immunoglobulin-E production
Plana	1997	Tematica delirante psicotica en psicopatologia de la expresion pictoria. Mitologemas.
WO2001038394A3 (en)	2002-05-02	Polypetptides and methods for thymic vaccination